Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? by Lambertini, Matteo et al.
  1Lambertini M, et al. ESMO Open 2018;3:e000350. doi:10.1136/esmoopen-2018-000350
Open Access 
Controversies in oncology: which 
adjuvant endocrine therapy is to be 
given to premenopausal patients 
with hormone receptor-positive 
breast cancer?
Matteo Lambertini,1,2 Giulia Viglietti,2 Evandro de Azambuja1 
Editorial
To cite: Lambertini M, 
Viglietti G, de Azambuja E. 
Controversies in oncology: 
which adjuvant endocrine 
therapy is to be given to 
premenopausal patients with 
hormone receptor-positive 
breast cancer? ESMO Open 
2018;3:e000350. doi:10.1136/
esmoopen-2018-000350
Received 6 March 2018
Accepted 7 March 2018
1Department of Medicine, 
Institut Jules Bordet, Université 
Libre de Bruxelles (ULB), 
Brussels, Belgium
2Breast Cancer Translational 
Research Laboratory, Institut 
Jules Bordet, Université Libre 
de Bruxelles (ULB), Brussels, 
Belgium
Correspondence to
Dr Matteo Lambertini;  matteo. 
lambertini85@ gmail. com
Although young women with newly diagnosed 
breast cancer are at increased risk of devel-
oping more aggressive tumour subtypes as 
compared with older patients, most of them 
are diagnosed with hormone receptor-pos-
itive (ie, luminal-like) disease.1 Hence, the 
majority of premenopausal women with early 
stage breast cancer are candidates to receive 
adjuvant endocrine therapy. Young age is 
considered a risk factor for breast cancer 
recurrence and death, particularly in women 
with luminal-like breast cancer.2 Hence, the 
choice of the most appropriate adjuvant 
endocrine therapy is of crucial importance 
particularly in premenopausal patients.
For more than two decades, tamoxifen 
alone has been considered the standard 
of care as adjuvant endocrine therapy for 
all premenopausal patients with hormone 
receptor-positive breast cancer.3 4 Neverthe-
less, in the last few years, the adjuvant endo-
crine treatment landscape of premenopausal 
patients with breast cancer has dramatically 
changed and the choice of the best approach 
to be used in this setting has become partic-
ularly complex. In fact, important new data 
on the role of ovarian function suppression 
(OFS) in addition to tamoxifen or its possible 
combination with an aromatase inhibitor 
(AI) have recently become available and 
should now be discussed with all premeno-
pausal women candidates to receive adjuvant 
endocrine therapy.5
Two studies (the E-3193, INT-01426 trials 
and the Suppression of Ovarian Function Trial 
(SOFT)7 8) provided evidence on the role of 
OFS in addition to tamoxifen in these patients. 
In the E-3193, INT-0142 trial, 345 premeno-
pausal women at low clinical risk of recurrence 
(use of chemotherapy was not allowed) were 
randomised to receive tamoxifen alone or 
tamoxifen plus OFS for 5 years.6 The SOFT 
randomly assigned 3066 premenopausal 
women to receive 5 years of tamoxifen alone, 
tamoxifen plus OFS or the AI exemestane plus 
OFS.7 8 In the primary analysis of the SOFT 
testing the benefit of adding OFS to tamox-
ifen, 2033 patients were included of whom 
53% received chemotherapy before randomi-
sation due to higher clinical risk of recurrence 
(importantly, patients with prior exposure to 
cytotoxic therapy could be enrolled within 8 
months after chemotherapy completion only 
if premenopausal status was confirmed). Taken 
together, the results from these two trials have 
suggested that the addition of OFS to tamox-
ifen does not provide any benefit in women at 
low clinical risk of recurrence for whom tamox-
ifen alone should be still considered standard 
of care.9–11 On the contrary, the addition of 
OFS to tamoxifen showed to significantly 
improve the outcomes of women considered at 
higher clinical risk of recurrence. At a median 
follow-up of 8 years, the addition of OFS to 
tamoxifen in patients exposed to chemo-
therapy in the SOFT was associated with a 5.3% 
absolute benefit in disease-free survival (DFS; 
HR 0.76, 95% CI 0.60 to 0.97) and a 4.3% abso-
lute benefit in overall survival (OS; HR 0.59, 
95% CI 0.42 to 0.84).8 The benefit of adding 
OFS was even greater in patients younger 
than 35 years of age at the time of diagnosis.12 
Importantly, when discussing with patients the 
combination of tamoxifen plus OFS, women 
should be made aware of the worse endocrine 
symptoms and sexual functioning (ie, hot 
flushes, loss of sexual interest, vaginal dryness 
and sleep disturbance) experienced with this 
combination particularly during the first 2 
years of therapy and in those with no prior 
exposure to chemotherapy.13
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While the role of OFS in premenopausal patients 
with higher clinical risk of recurrence (ie, those who 
are normally candidates also to (neo)adjuvant chemo-
therapy) is now well established and recommended by all 
major guidelines,9–11 the best partner (tamoxifen or an 
AI) to be combined with OFS remains highly debated. In 
fact, the combination of an AI plus OFS is now considered 
another available treatment option for these patients.9–11 
However, the two large studies that investigated this 
strategy (the Austrian Breast and Colorectal Cancer Study 
Group 12 (ABCSG-12) trial14 and the joint analysis of the 
SOFT and Tamoxifen and Exemestane Trial (TEXT)15 16) 
showed conflicting results.
In the ABCSG-12 trial, 1803 premenopausal patients at 
low clinical risk of recurrence (only 5% received neoadju-
vant chemotherapy and none received adjuvant cytotoxic 
therapy) were randomised to receive OFS with goserelin 
plus tamoxifen or the AI anastrozole with or without 
zoledronic acid for 3 years.14 With a median follow-up of 
approximately 8 years, no difference was observed in DFS 
between the two arms (HR 1.13, 95% CI 0.88 to 1.45), but 
OS was significantly worse in patients who received anas-
trozole (HR 1.63, 95% CI 1.05 to 2.52).14 Importantly, it 
should be noted that differently from the SOFT and TEXT, 
the ABCSG-12 study included only a patients’ population 
at low risk of relapse, administering a non-standard 3-year 
duration of endocrine therapy and adjuvant bisphospho-
nates in half of the included patients.
In the joint analysis of the SOFT and TEXT, 4690 
patients were randomised to receive OFS plus tamox-
ifen or the AI exemestane for 5 years.15 16 Among these 
patients, 57% received chemotherapy before randomi-
sation due to higher clinical risk of recurrence (impor-
tantly, in the TEXT, OFS with triptorelin was started 
concomitantly with chemotherapy). Updated results at a 
median follow-up of 9 years showed that, in the overall 
study population, OFS plus exemestane significantly 
improved DFS (4.0% absolute benefit; HR 0.77, 95% CI 
0.67 to 0.90) but no difference in OS was observed (HR 
0.98, 95% CI 0.79 to 1.22). The benefit was larger in 
patients who received chemotherapy before adjuvant 
endocrine therapy.16 To help physicians in individualising 
endocrine therapy decision-making, a sophisticated anal-
ysis using the non-parametric sliding-window subpopula-
tion treatment effect pattern plot (STEPP) methodology 
was conducted within the SOFT and TEXT.17 The authors 
examined the absolute treatment effect across a contin-
uous composite measure of recurrence risk for each 
patient determined on the basis of their clinical patho-
logical characteristics (ie, age, nodal status, tumour size, 
grade, oestrogen and progesterone receptors and Ki67 
expression levels). This analysis showed that the greater 
benefit of combining OFS plus AI was observed in women 
with high risk of recurrence who received chemotherapy 
and in those who did not undergo chemotherapy but had 
higher-risk characteristics. The benefit of OFS plus AI 
over OFS plus tamoxifen was moderate in patients who 
received chemotherapy but had an intermediate risk of 
recurrence.17
In the treatment decision-making for the choice 
between OFS plus tamoxifen or an AI, it is crucial to 
discuss with all premenopausal patients not only the 
expected benefit based on the individual risk of recur-
rence but also the different toxicity profile of these two 
options, the important issue of compliance and adher-
ence to treatment as well as the timing of administering 
pharmacological OFS.
The patient-reported outcomes of the SOFT and TEXT 
showed small and similar changes in the global quality 
of life indicators between the combination of OFS with 
tamoxifen or exemestane.18 However, these two treat-
ment options showed a different toxicity profile: over the 
5 years of treatment, hot flushes and sweats were common 
with the use of tamoxifen while bone or joint pain, vaginal 
dryness, greater loss of sexual interest and difficulties of 
becoming aroused with exemestane.18 Therefore, the 
different toxicity profile should be clearly discussed indi-
vidually with all patients before making a final decision 
considering the major role that these side effects can have 
on their daily life.
Moreover, it should be highlighted that young patients 
with breast cancer have poor compliance to endocrine 
therapy19; fertility concerns are among the key factors 
for both non-initiation and early discontinuation of such 
treatment.20 21 In the SOFT and TEXT, up to 20% of the 
patients stopped all protocol-assigned therapy earlier than 
5 years; the rate of non-adherence to endocrine therapy 
was even higher for women diagnosed under the age of 35 
years with 23% and 25% who interrupted triptorelin and 
oral endocrine therapy at 4 years, respectively.12 On this 
regard, it is important to highlight that, for administering 
AI in premenopausal patients, a complete OFS is required 
while this is not the case for tamoxifen. This is an issue of 
crucial importance when pharmacological OFS is used. 
As shown in the SOFT-EST substudy, the combination of 
triptorelin and exemestane led to a more profound OFS 
than triptorelin plus tamoxifen.22 However, up to 20% 
of the patients undergoing triptorelin plus exemestane 
had incomplete OFS during treatment; this risk seems to 
be higher for patients not previously exposed to chemo-
therapy22 and in those with higher body mass index.22 23 
Hence, although routine monitoring of estradiol levels in 
patients undergoing pharmacological OFS is not recom-
mended, when an AI is its partner of choice, physicians 
should be aware about the possible occurrence of physi-
ological changes suggestive for ovarian function recovery 
(eg, menstrual resumption and/or cyclical fluctuations in 
climacteric symptoms).9 In these cases, the AI should be 
changed to tamoxifen in addition to OFS. For the same 
reason, when compliance with monthly injection cannot 
be guaranteed, the combination of OFS and an AI should 
not be considered the best treatment approach.
Finally, regarding the timing of administering pharma-
cological OFS in patients who are candidates to chemo-
therapy, it may be considered to start its use during 
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cytotoxic therapy instead of waiting for the end of treat-
ment. In fact, concurrent administration of OFS and 
chemotherapy was shown to be safe24 25 and has the poten-
tial to reduce the risk of treatment-induced premature 
ovarian insufficiency and infertility,26–28 an issue of great 
importance for many young patients with breast cancer.
In conclusion, it has become rather complex to decide 
the best adjuvant endocrine therapy option for a given 
patient and even more the choice between tamoxifen or 
an AI when OFS is recommended (figure 1). Importantly, 
during treatment decision-making, patients should be 
adequately and extensively informed about the pros and 
contras of the different options; moreover, they should 
be closely monitored and engaged during the oncolog-
ical follow-up to increase their treatment compliance and 
thus improving their long-term outcomes. Final results 
of the ongoing phase III HOrmonal adjuvant treat-
ment BOne Effects study ( ClinicalTrials. gov Identifier: 
NCT00412022) are awaited to give further insights on 
what’s the best choice between tamoxifen and an AI as 
adjuvant endocrine therapy in premenopausal patients 
with breast cancer who are candidates to receive OFS.
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